Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
76
Completed, industry sponsors, Rare and genetic disease, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
76 trials
Showing 1 to 25, recently updated first.
Sangamo TherapeuticsIndustry
NCT04046224 · 36 participants · Start Jul 23, 2019 · Primary completion Apr 10, 2025
Drug: ST-920 · For: Fabry Disease
Sites: Irvine, California; Tampa, Florida; Atlanta, Georgia · 18 sites in all
Nacuity Pharmaceuticals, Inc.Industry
NCT05994534 · 8 participants · Start Oct 29, 2023 · Primary completion May 26, 2026
Drug: Cysteamine Bitartrate; N-Acetylcysteine Amide · For: Cystinosis
Sites: Westmead, Australia
- First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With PhenylketonuriaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT05781399 · 163 participants · Start Oct 31, 2022 · Primary completion Jul 29, 2025
Drug: JNT-517 Suspension; Placebo Suspension and 2 more · For: Phenylketonuria
Sites: Gainesville, Florida; Tampa, Florida; Atlanta, Georgia · 15 sites in all
Aro BiotherapeuticsIndustry
NCT06109948 · 46 participants · Start Oct 19, 2023 · Primary completion Feb 13, 2026
Drug: ABX1100 injection for IV infusion; Placebo injection for IV infusion · For: Healthy; Late Onset Pompe Disease
Sites: Orange, California; St Louis, Missouri; Fairfax, Virginia · 5 sites in all
ShireTakeda (TAK)
NCT01887938 · 24 participants · Start May 23, 2013 · Primary completion Feb 13, 2026
Drug: HGT-1110 · For: Metachromatic Leukodystrophy (MLD)
Sites: Westmead, Australia; Porto Alegre, Brazil; Brno, Czechia · 15 sites in all
Amicus TherapeuticsIndustry
NCT02675465 · 29 participants · Start Apr 2016 · Primary completion Aug 22, 2024
Drug: ATB200; AT2221 · For: Pompe Disease
Sites: Phoenix, Arizona; Orange, California; Gainesville, Florida · 19 sites in all
Bio Sidus SAIndustry
NCT05343715 · 24 participants · Start Oct 23, 2021 · Primary completion Mar 6, 2022
Drug: Agalsidase beta from Biosidus 1 mg/kg; Fabrazyme (agalsidase beta) 1 mg/kg · For: Fabry Disease
Sites: Ciudadela, Argentina
- An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)Completed
JCR Pharmaceuticals Co., Ltd.Industry
NCT04453085 · 14 participants · Start Oct 28, 2021 · Primary completion May 2, 2025
Drug: JR-171 · For: Mucopolysaccharidosis I
Sites: Oakland, California; Porto Alegre, Brazil; São Paulo, Brazil · 6 sites in all
TakedaTakeda (TAK)
NCT01506141 · 15 participants · Start Aug 1, 2010 · Primary completion Apr 30, 2024
Drug: Idursulfase-IT; Elaprase · For: Hunter Syndrome
Sites: Chicago, Illinois; Chapel Hill, North Carolina; Portland, Oregon · 9 sites in all
JCR Pharmaceuticals Co., Ltd.Industry
NCT04227600 · 18 participants · Start Sep 1, 2020 · Primary completion Aug 2, 2022
Drug: JR-171 (lepunafusp alfa) · For: Mucopolysaccharidosis I
Sites: Oakland, California; Porto Alegre, Brazil; São Paulo, Brazil · 6 sites in all
- CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food InteractionCompleted
Connecta Therapeutics, S.L.Industry
NCT06480968 · 76 participants · Start Jun 23, 2023 · Primary completion Nov 11, 2024
Drug: CTH120 · For: Fragile X Syndrome
Sites: Barcelona, Spain
AmgenAmgen (AMGN)
NCT00872729 · 9 participants · Start May 2009 · Primary completion Oct 2009
Drug: Cystagon®; RP103 · For: Cystinosis
Sites: San Diego, California
AO GENERIUMIndustry
NCT06475404 · 18 participants · Start Apr 6, 2023 · Primary completion Sep 20, 2023
Drug: verenafusp alfa 6 mg/kg; verenafusp alfa 9 mg/kg and 1 more · For: Mucopolysaccharidosis Type II; Metabolic Diseases
Sites: Moscow, Russia
SanofiSanofi (SNY)
NCT06188325 · 18 participants · Start Jan 1, 2018 · Primary completion Mar 26, 2018
Drug: Eliglustat · For: Gaucher's Disease
Sites: Dallas, Texas
- A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the MouthCompleted
SanofiSanofi (SNY)
NCT06193304 · 6 participants · Start Aug 25, 2014 · Primary completion Sep 21, 2014
Drug: Eliglustat · For: Gaucher's Disease
Sites: Evansville, Indiana
Swedish Orphan BiovitrumIndustry
NCT04765553 · 8 participants · Start Jan 14, 2021 · Primary completion Jun 25, 2021
Drug: NI-0501; Saline · For: Rare Diseases
Sites: Tokyo, Japan
SanofiSanofi (SNY)
NCT06143904 · 10 participants · Start Jun 3, 2009 · Primary completion Jul 5, 2009
Drug: Genz-112638; Genz-112638 and 1 more · For: Gaucher's Disease Type I
PTC TherapeuticsIndustry
NCT03519711 · 8 participants · Start Jan 3, 2019 · Primary completion Oct 2, 2020
Drug: PTC923 · For: BH4 Deficiency; Hyperphenylalaninemia
Sites: Minneapolis, Minnesota; Dallas, Texas; Salt Lake City, Utah · 4 sites in all
Gradalis, Inc.Industry
NCT02736565 · 7 participants · Start Oct 2016 · Primary completion Aug 12, 2019
Drug: pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex · For: Ewing's Sarcoma; Ewing Family of Tumors; Ewing's Tumor Metastatic and 4 more
Sites: New York, New York; Dallas, Texas
ItalfarmacoIndustry
NCT01761292 · 20 participants · Start Apr 2013 · Primary completion Dec 2014
Drug: Givinostat · For: Duchenne Muscular Dystrophy (DMD)
Sites: Messina, Italy; Milan, Italy; Roma, Italy · 4 sites in all
ProtalixIndustry
NCT01678898 · 18 participants · Start Oct 2012 · Primary completion Mar 6, 2016
Drug: PRX-102 · For: Fabry Disease
Sites: Sacramento, California; Atlanta, Georgia; Iowa City, Iowa · 14 sites in all
ProtalixIndustry
NCT01981720 · 15 participants · Start Jan 16, 2014 · Primary completion Aug 26, 2020
Drug: PRX-102 (pegunigalsidase alfa) · For: Fabry Disease
Sites: Gainesville, Florida; Iowa City, Iowa; Baltimore, Maryland · 8 sites in all
Klus Pharma Inc.Industry
NCT03602079 · 49 participants · Start Jul 16, 2018 · Primary completion Jan 12, 2022
Drug: A166 · For: HER2-positive Breast Cancer; HER2 Gene Mutation; HER-2 Gene Amplification and 41 more
Sites: Sarasota, Florida; Boston, Massachusetts; Detroit, Michigan · 10 sites in all
- Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.Completed
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01898364 · 24 participants · Start Aug 19, 2013 · Primary completion Feb 25, 2015
Drug: GZ402666 · For: Pompe Disease; Glycogen Storage Disease Type II (GSD II); Acid Maltase Deficiency
Sites: Phoenix, Arizona; Jacksonville, Florida; Kansas City, Kansas · 17 sites in all
ArmaGen, IncIndustry
NCT03071341 · 19 participants · Start Oct 2016 · Primary completion Feb 1, 2018
Drug: AGT-181 · For: Mucopolysaccharidosis I
Sites: Porto Alegre, Brazil
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.